Andrew Green Sells 44,001 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 44,001 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the sale, the senior vice president directly owned 60,259 shares in the company, valued at $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Artivion Trading Up 3.3%

Shares of AORT traded up $0.66 during mid-day trading on Monday, hitting $20.76. The company had a trading volume of 300,307 shares, compared to its average volume of 531,476. The business’s 50-day simple moving average is $28.92 and its 200-day simple moving average is $36.98. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The stock has a market cap of $1.01 billion, a PE ratio of 86.42 and a beta of 1.27.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AORT. Aster Capital Management DIFC Ltd raised its holdings in Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after buying an additional 519 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Artivion in the third quarter valued at approximately $27,000. Rockefeller Capital Management L.P. raised its holdings in Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after buying an additional 399 shares during the period. Larson Financial Group LLC raised its holdings in Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after buying an additional 563 shares during the period. Finally, USA Financial Formulas raised its holdings in Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after buying an additional 703 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analyst Ratings Changes

AORT has been the topic of several research analyst reports. LADENBURG THALM/SH SH raised shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research report on Friday, April 10th. Citizens Jmp decreased their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday, May 8th. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research report on Monday, June 1st. Needham & Company LLC decreased their target price on shares of Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, Weiss Ratings cut shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 8th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Artivion currently has a consensus rating of “Moderate Buy” and an average price target of $46.17.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.